RxDoctor Payments Data

Angela Dahle, MD

Rheumatology · Edina, MNNPI 1629121645

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $869 of the $1,207 with a category attached, or 72.0%. 14 manufacturers reported payments, led by Amgen at 43.1% of the total.

$1,207in general payments, 2019–2025

Across 49 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$520
  • Johnson & Johnson$158
  • AbbVie$89
  • Abbott$73
  • Pfizer$64
  • Sanofi$57
  • plus $246 from 8 others

What the payments were for

  • Travel & lodging$33828%
  • Food & beverage$86972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,207 in reported general payments places this provider in the 75th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$576,611
Medicare patients
179
Services billed
33,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab24$246,139
Xeljanz XrTofacitinib Citrate19$132,222
SimponiGolimumab14$92,161
EnbrelEtanercept12$89,860
Hydroxychloroquine Sulfate320$16,424
PlaquenilHydroxychloroquine Sulfate16$15,736
MethotrexateMethotrexate Sodium267$10,654
Azathioprine67$5,300
Cevimeline Hcl22$4,279
Prednisone325$3,488
Leflunomide61$2,699
Mycophenolate Mofetil24$2,557
Sulfasalazine DrSulfasalazine42$2,539
Celecoxib83$2,367
Pilocarpine Hcl20$2,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi$158$92,16114 claims
AmgenEnbrel$520$89,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →